Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum

Per Ljungman(Karolinska University Hospital), Dana G. Wolf(Hadassah Medical Center), Yoichiro Natori(University of Miami), Raymund R. Razonable(Mayo Clinic in Florida), Atul Humar(University Health Network), Paul Griffiths(University College London), Monica A. Slavin(The Royal Melbourne Hospital), Aimee Hodowanec(United States Food and Drug Administration), Cyrus Badshah(Merck & Co., Inc., Rahway, NJ, USA (United States)), Oriol Manuel(University Hospital of Lausanne), Veronica Miller(University of California, Berkeley), Angie Caliendo, Martha Fournier(Takeda (United States)), David Navarro(INCLIVA Health Research Institute), Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Michael Boeckh(University of Washington), Andreas Pikis(United States Food and Drug Administration), Michelle Wong, Sophie Alain(Inserm), Parmjeet Randhawa(University of Pittsburgh), Gabriel Westman(Uppsala University), Sunwen Chou, Fareed Khawaya(The University of Texas MD Anderson Cancer Center), Andreas Piki, Takashi Komatsu(United States Food and Drug Administration), Camille N. Kotton(Harvard University), Ajit P. Limaye(University of Washington), Robin K. Avery(Johns Hopkins University)
Clinical Infectious Diseases
July 23, 2024
Cited by 145


Related Papers